ArticleBriefings in bioinformatics2025
GraphATC: advancing multilevel and multi-label anatomical therapeutic chemical classification via atom-level graph learning.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Multimodal Sequence-to-Sequence Model for Automatic Assignment of ATC Codes in Drug Discovery and Repurposing.Journal of chemical information and modeling · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The accurate categorization of compounds within the anatomical therapeutic chemical (ATC) system is fundamental for drug development and fundamental research. Although this area has garnered significant research focus for over a decade, the majority of prior studies have concentrated solely on the Level 1 labels defined by the World Health Organization (WHO), neglecting the labels of the remaining four levels. This narrow focus fails to address the true nature of the task as a multilevel, multi-label classification challenge. Moreover, existing benchmarks like Chen-2012 and ATC-SMILES have become outdated, lacking the incorporation of new drugs or updated properties of existing ones that have emerged in recent years and have been integrated into the WHO ATC system. To tackle these shortcomings, we present a comprehensive approach in this paper. Firstly, we systematically cleanse and enhance the drug dataset, expanding it to encompass all five levels through a rigorous cross-resource validation process involving KEGG, PubChem, ChEMBL, ChemSpider, and ChemicalBook. This effort culminates in the creation of a novel benchmark termed ATC-GRAPH. Secondly, we extend the classification task to encompass Level 2 and introduce graph-based learning techniques to provide more accurate representations of drug molecular structures. This approach not only facilitates the modeling of Polymers, Macromolecules, and Multi-Component drugs more precisely but also enhances the overall fidelity of the classification process. The efficacy of our proposed framework is validated through extensive experiments, establishing a new state-of-the-art methodology. To facilitate the replication of this study, we have made the benchmark dataset, source code, and web server openly accessible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.